Rutgers Swimmer Brooke Thompson Named SHI Brand Ambassador
Thompson, a rising junior at Rutgers University, holds the USA Deaf Swimming Record in the 50-meter freestyle (23.53), which she set at the 2025 Big Ten Championships. The Bloomfield Hills, Michigan, native also captured the ECAC 200 Medley Relay Championship in March. Born completely deaf, Thompson is an advocate for adaptive technology and workplace inclusion for individuals with disabilities. She received her first cochlear implant at age 1 and her second at 4.
Thompson joins LPGA Tour golfers Jennifer Kupcho, Gurleen Kaur, and Allisen Corpuz, as well as North Carolina Courage and U.S. Women's National Team goalkeeper Casey Murphy, on the company's team of brand ambassadors.
'Brooke embodies the qualities we value most at SHI: dedication, perseverance, and a commitment to helping others succeed,' said Ed McNamara, Senior Director of Communications at SHI. 'Her athletic achievements are remarkable, but what truly sets Brooke apart is her willingness to share her story, answer every question and advocate for greater awareness of adaptive technologies that can help level the playing field. We're thankful that Brooke is joining the SHI brand and look forward to supporting her journey to Tokyo and beyond.'
Thompson discovered her passion for swimming after her parents enrolled her in lessons for safety reasons. While the Thompson family enjoyed Michigan's abundance of lakes and summertime water sports, swimming can pose a unique set of challenges for beginners with cochlear implants. Concerned that it may be difficult to communicate with Brooke during a potential emergency, her parents encouraged her to become the best possible swimmer in the water.
She has since won 11 medals in two World Deaf Swimming Championships and won five gold medals and three bronze medals in the 2022 Deaflympics in Brazil.
'Swimming has given me opportunities I never imagined, from competing at the highest level to connecting with the deaf community worldwide,' Thompson said. 'Partnering with SHI feels natural because they understand that success comes from hard work, collaboration and a culture that ensures all people have the tools they need to succeed or the ability to request them. I'm eager to represent SHI while showing that with the right technologies and mindset, barriers can become steppingstones.'
Thompson, who is majoring in business leadership and management, first told her story to SHI customers, partners, and employees at an SHI End User Computing Summit in 2024. Addressing a 300-preson audience responsible for supporting tens of thousands of end-users around the globe, Thompson raised awareness about the importance of ensuring businesses have both the policies and inclusive culture in place to ensure employees have – or feel free to request – whatever adaptive technologies they need. Her advocacy focuses on helping organizations understand that simple accommodations can make profound differences for employees with disabilities.
As a member of the delegation the USA Deaf Sports Federation (USADF) is sending to 2025 Deaflympics in Tokyo this November, Thompson will compete against deaf and hard-of-hearing athletes from around the world, where all participants compete without hearing assistance to ensure equal competition conditions.
About SHI
SHI International Corp. is a $15 billion transformational technology solutions provider serving the needs of more than 15,000 corporate, enterprise, public sector and academic customer organizations around the world. It helps companies achieve business goals through the use of technologies ranging from software licensing and end user computing devices to innovative cloud and edge solutions. With over 6,000 employees worldwide, SHI is the largest Minority and Woman Owned Business Enterprise (MWBE) in the U.S.
To learn more about SHI, please visit
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
Access Advance Announces HEVC Advance and VVC Advance Pricing through 2030
BOSTON--(BUSINESS WIRE)--Access Advance LLC ('Advance') today announced the results of several significant decisions by the Licensors in both the HEVC Advance and VVC Advance Patent Pools. Both patent pools opted to maintain their current royalty rates and caps for Licensees who sign before December 31, 2025, and to extend an incentive that aligns the royalty caps for Advance's Multi-Codec Bridging Agreement ('MCBA') and the VVC Advance Patent Pool for Licensees who sign the MCBA during the same period. Access Advance is pleased that both groups of Licensors opted for marketplace stability and predictability with their decisions largely to maintain rates and caps at existing levels and providing an additional incentive for Licensees to sign the MCBA. Share The result is that Licensees who join the HEVC Advance program, gaining access to more than 27,000 patents, on or before December 31, 2025, can lock in current rates and caps through 2030. This protection applies both to ongoing royalty obligations and calculation of royalties due for past sales. Additionally, both current and new HEVC Advance Licensees who join the VVC Advance Patent Pool and execute the MCBA by December 31, 2025, will enjoy MCBA royalty caps that match the royalty caps for the VVC Advance program. This reflects an extension of an incentive that expired June 30, 2022, and locks in current rates through 2030, effectively reducing the current MCBA royalty caps and reinforcing Access Advance's commitment to rewarding early adopters of its platform licensing approach. Beginning on January 1, 2026, the HEVC royalty rates will be updated to align HEVC Advance pricing with the existing VVC Advance royalty rate structure, which the VVC Advance Licensors voted to maintain at current levels through 2030, making the value proposition of the MCBA even more beneficial for Licensees across Access Advance's video codec platform licensing programs. "Access Advance is pleased that both groups of Licensors opted for marketplace stability and predictability with their decisions largely to maintain rates and caps at existing levels and providing an additional incentive for Licensees to sign the MCBA. After nearly a decade of stable HEVC rates, the measured adjustment for Licensees joining after 2025 reflects the tremendous growth and value that the HEVC Advance Patent Pool now delivers to the marketplace in light of the increased prevalence of HEVC devices and content," said Peter Moller, CEO of Access Advance. "When we launched, we anticipated coverage of approximately 35% of all HEVC standard essential patents. Today, our pool represents an estimated 75-80% of the global HEVC patent landscape – more than doubling our initial projections. The approved rate adjustment of 25%, which will go into effect for new Licensees on January 1, 2026, while less than a full doubling that our coverage would justify, ensures fair compensation for innovators while maintaining our commitment to transparent, FRAND licensing. And, with these changes, there are clear benefits to a company joining our VVC program and securing the MCBA's discounts even if their products do not yet include VVC functionality." Industry-Leading Patent Coverage The HEVC Advance Patent Pool has evolved from its initial launch with fewer than 500 patents to become the industry's most comprehensive licensing solution, now covering over 27,000 patents essential to H.265/HEVC technology. This dramatic expansion represents the largest consolidation of HEVC standard-essential patents available through any single licensing program globally. The patent pool's success in attracting major patent holders demonstrates the market's confidence in Access Advance's balanced approach to intellectual property licensing. Recent additions include leading technology companies across mobile devices, consumer electronics, automotive, and emerging IOT applications. Opportunity for Flexibility, Savings and Efficiencies Access Advance encourages both current licensees and prospective partners to evaluate their multi-codec licensing strategies before the December 31, 2025 deadline. Companies implementing both HEVC and next-generation VVC technologies can realize significant cost savings and operational efficiencies through the MCBA structure. The alignment of HEVC rates with VVC rates also creates opportunities for companies to adopt a unified approach to video codec licensing across their product portfolios, simplifying compliance obligations while accessing the industry's most comprehensive patent coverage, and providing maximum flexibility for future technology adoption. For licensing inquiries and detailed rate information, interested parties should contact Access Advance at licensing@ About Access Advance: Access Advance LLC is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers. Access Advance manages and administers the HEVC Advance Patent Pool for licensing over 27,000 patents essential to H.265/HEVC technology and the VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. The company's Multi-Codec Bridging Agreement provides eligible licensees with a single discounted royalty rate structure for licensees participating in both the HEVC Advance and VVC Advance pools. In addition, Access Advance offers the VDP Pool, a comprehensive licensing solution for video streaming services covering HEVC, VVC, VP9, and AV1 codecs. For more information, please visit:
Business Wire
23 minutes ago
- Business Wire
Green Dot to Announce Second Quarter 2025 Results on August 11th
PROVO, Utah--(BUSINESS WIRE)--Green Dot Corporation (NYSE: GDOT) will host a conference call and earnings webcast to discuss second quarter 2025 financial results on Monday, August 11th, 2025 at 5:00 p.m. ET. A press release with the company's second quarter 2025 financial results will be issued after the market closes on the same day. The live webcast of the call can be accessed from Green Dot's investor relations website at A replay will be available at the same website following the call. About Green Dot Green Dot Corporation (NYSE: GDOT) is a financial technology platform and registered bank holding company that builds banking and payment solutions to create value, retain and reward customers, and accelerate growth for businesses of all sizes. For more than two decades, Green Dot has delivered financial tools and services that address the most pressing financial needs of consumers and businesses, and that transform the way people and businesses manage and move money Green Dot delivers a broad spectrum of financial products to consumers and businesses through its portfolio of brands, including: GO2bank, a leading digital and mobile bank account offering simple, secure and useful banking for Americans living paycheck to paycheck; the Green Dot Network ('GDN') of more than 95,000 retail distribution and cash access locations nationwide; Arc by Green Dot, the single-source embedded finance platform combining all of Green Dot's secure banking and money processing capabilities to power businesses at all stages of growth; rapid! wage and disbursements solutions, providing pay card and earned wage access services to more than 6,000 businesses and their employees; and Santa Barbara TPG ('SBTPG'), the company's tax division, which processes approximately 14 million tax refunds annually. Founded in 1999, Green Dot has managed more than 80 million accounts to date both directly and through its partners. Green Dot Bank is a subsidiary of Green Dot Corporation and member of the FDIC. For more information about Green Dot's products and services, please visit
Business Wire
an hour ago
- Business Wire
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today, Sarepta Therapeutics notified the U.S. Food and Drug Administration (FDA) of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025. This proactive step will allow Sarepta the necessary time to respond to any requests for information and allow Sarepta and FDA to complete the ELEVIDYS safety labeling supplement process. The Company looks forward to a collaborative, science-driven review process and dialogue with the FDA. 'As a patient-centric organization, the decision to voluntarily and temporarily pause shipments of ELEVIDYS was a painful one, as individuals with Duchenne are losing muscle daily and in need of disease-modifying options,' said Doug Ingram, chief executive officer, Sarepta. 'It is important for the patients we serve that Sarepta maintains a productive and positive working relationship with FDA, and it became obvious that maintaining that productive working relationship required this temporary suspension while we address any questions that FDA may have and complete the ELEVIDYS label supplement process.' Sarepta remains committed to transparency and patient safety and will continue to provide timely updates to patients, families, healthcare providers, and the broader Duchenne community as additional information becomes available. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, ELEVIDYS, ongoing interactions with FDA related to ELEVIDYS, and our decision to voluntarily and temporarily pause shipments of ELEVIDYS in the United States. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, the results of future research may not be consistent with past positive results, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us.
